Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. (Q53634365)

16 May 2018

title

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. (English)

1 reference

16 May 2018

author

Angela Dispenzieri

16

1 reference

16 May 2018

Rafael Fonseca

18

1 reference

16 May 2018

Morie A Gertz

14

Gertz MA

1 reference

16 May 2018

Martha Q Lacy

15

Lacy MQ

1 reference

16 May 2018

Scott A Van Wier

3

Van Wier SA

1 reference

16 May 2018

Rafael Santana-Davila

2

Santana-Dávila R

1 reference

16 May 2018

author name string

Chng WJ

1

1 reference

16 May 2018

Ahmann GJ

4

1 reference

16 May 2018

Jalal SM

5

1 reference

16 May 2018

Bergsagel PL

6

1 reference

16 May 2018

Chesi M

7

1 reference

16 May 2018

Trendle MC

8

1 reference

16 May 2018

Jacobus S

9

1 reference

16 May 2018

Blood E

10

1 reference

16 May 2018

Oken MM

11

1 reference

16 May 2018

Henderson K

12

1 reference

16 May 2018

Kyle RA

13

1 reference

16 May 2018

Greipp PR

17

1 reference

16 May 2018

publication date

1 May 2006

1 reference

16 May 2018

published in

Leukemia

1 reference

16 May 2018

volume

20

1 reference

16 May 2018

issue

5

1 reference

16 May 2018

page(s)

807-813

1 reference

16 May 2018

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Bone lesions in molecular subtypes of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Genetics and cytogenetics of multiple myeloma: a workshop report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Hypodiploidy is a major prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404172

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404172

1 reference

16 May 2018

1 reference

16 May 2018